scholarly journals New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain

2017 ◽  
Vol 23 (2_suppl) ◽  
pp. 166-178 ◽  
Author(s):  
Celia Oreja-Guevara ◽  
Gisela Kobelt ◽  
Jenny Berg ◽  
Daniela Capsa ◽  
Jennifer Eriksson ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Work Capacity ◽  
Outcome Data ◽  
Current Data ◽  
Cross Sectional ◽  
Cognitive Difficulties ◽  
Related Quality ◽  
Experienced Fatigue ◽  
Health Related ◽  
Mean Cost

Introduction: In order to estimate the value of interventions in multiple sclerosis (MS) where lifetime costs and outcomes cannot be observed, outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015. Results: A total of 462 patients (mean age 43 years) participated in Spain; 96% were below retirement age and of these, 45% were employed. Employment was related to disability, and MS affected productivity at work for 72% of those working. Overall, 92% and 64% of patients experienced fatigue and cognitive difficulties as a problem, respectively. Mean utility and total annual costs were estimated at 0.772 and €20,600 at Expanded Disability Status Scale (EDSS) 0–3, 0.486 and €48,500 at EDSS 4–6.5 and 0.182 and €68,700 at EDSS 7–9, respectively. The mean cost of a relapse was €2050. Conclusion: This study illustrates the burden of MS on Spanish patients and provides current data that are important for development of health policies.

scholarly journals New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium

2017 ◽  
Vol 23 (2_suppl) ◽  
pp. 29-40 ◽  
Author(s):  
Benedicte Dubois ◽  
Gisela Kobelt ◽  
Jenny Berg ◽  
Daniela Capsa ◽  
Mia Gannedahl ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Work Capacity ◽  
Outcome Data ◽  
Current Data ◽  
Cross Sectional ◽  
Cognitive Difficulties ◽  
Related Quality ◽  
Experienced Fatigue ◽  
Health Related ◽  
Mean Cost

Introduction: In order to estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015. Results: A total of 1856 patients (mean age: 54 years) participated in Belgium; 66% were below retirement age, and of these, 44% were employed. Employment was related to disease severity, and MS affected productivity at work in 85% of the patients. Overall, 95% and 72% of the patients experienced fatigue and cognitive difficulties, respectively, as a problem. Mean utility and annual costs were 0.703 and €26,400 at Expanded Disability Status Scale (EDSS) 0–3, 0.478 and €45,300 at EDSS 4–6.5, and 0.193 and €62,000 at EDSS 7–9. The mean cost of a relapse was estimated to be €3000. Conclusion: This study provides current data on MS in Belgium that are important for development of health policies and for estimating the value of current and future treatments.

scholarly journals New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy

2017 ◽  
Vol 23 (2_suppl) ◽  
pp. 104-116 ◽  
Author(s):  
Mario Battaglia ◽  
Gisela Kobelt ◽  
Michela Ponzio ◽  
Jenny Berg ◽  
Daniela Capsa ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Work Capacity ◽  
Outcome Data ◽  
Current Data ◽  
Cross Sectional ◽  
Cognitive Difficulties ◽  
Related Quality ◽  
Experienced Fatigue ◽  
Health Related ◽  
Mean Cost

Introduction: In order to estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015. Results: A total of 1010 patients (mean age = 45 years) participated in Italy. In total, 94% were below retirement age, and of these, 56% were employed. Employment was related to disability, and MS affected productivity at work in 77% of the patients. Overall, 96% and 65% of the patients experienced fatigue and cognitive difficulties as a problem, respectively. Mean utility and total annual costs were 0.735 and €22,900 at Expanded Disability Status Scale (EDSS) of 0–3, 0.534 and €40,100 at EDSS of 4–6.5, and 0.135 and €53,300 at EDSS of 7–9. The mean cost of a relapse was estimated to be €2600. Conclusion: This study illustrates the burden of MS on Italian patients and provides current data on MS that are important for the development of health policies.

scholarly journals New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria

2017 ◽  
Vol 23 (2_suppl) ◽  
pp. 17-28 ◽  
Author(s):  
Thomas Berger ◽  
Gisela Kobelt ◽  
Jenny Berg ◽  
Daniela Capsa ◽  
Mia Gannedahl ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Work Capacity ◽  
Outcome Data ◽  
Current Data ◽  
Cross Sectional ◽  
Disability Status ◽  
Related Quality ◽  
Experienced Fatigue ◽  
Health Related ◽  
Mean Cost

Introduction: In order to estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and Methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015. Results: A total of 516 patients (mean age, 53 years) participated in Austria; 72% were below retirement age, and of these, 46% were employed. Employment was related to disability, and MS affected productivity at work for 77% of those working. Overall, 94% and 67% of patients experienced fatigue and cognition as a problem. Mean utility and total annual costs were 0.778 and 25,100€ at Expanded Disability Status Scale (EDSS) 0–3, 0.579 and 44,100€ at EDSS 4–6.5, and 0.244 and 73,800€ at EDSS 7–9. The mean cost of a relapse was estimated at 2563€. Conclusion: This study illustrates the burden of MS on Austrian patients and provides current data on MS that are important for development of health policies.

scholarly journals New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany

2017 ◽  
Vol 23 (2_suppl) ◽  
pp. 78-90 ◽  
Author(s):  
Peter Flachenecker ◽  
Gisela Kobelt ◽  
Jenny Berg ◽  
Daniela Capsa ◽  
Mia Gannedahl ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Work Capacity ◽  
Outcome Data ◽  
Cross Sectional ◽  
Cognitive Difficulties ◽  
Related Quality ◽  
Experienced Fatigue ◽  
Health Related ◽  
The Mean ◽  
Mean Cost

Introduction: To estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015. Results: A total of 5475 patients (mean age 52 years) participated in Germany. In all, 84% were below retirement age, and of these, 51% were employed. Employment was related to disease severity, and MS affected productivity at work for 80% of patients. Overall, 96% and 78% of patients experienced fatigue and cognitive difficulties as a problem, respectively. The mean utility and total annual costs were 0.786 and 28,200€ at Expanded Disability Status Scale (EDSS) 0–3, 0.586 and €44,000 at EDSS 4–6.5 and 0.273 and €62,700 at EDSS 7–9, respectively. The mean cost of a relapse was estimated at €2500. Conclusion: This study provides current health economic data on MS in Germany that are important for the development of health policies and for estimating the value of the current and future treatments.

scholarly journals New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary

2017 ◽  
Vol 23 (2_suppl) ◽  
pp. 91-103 ◽  
Author(s):  
Márta Péntek ◽  
Gisela Kobelt ◽  
Jenny Berg ◽  
Daniela Capsa ◽  
Johan Dalén ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Work Capacity ◽  
Outcome Data ◽  
Current Data ◽  
Cross Sectional ◽  
Cognitive Difficulties ◽  
Disability Status ◽  
Related Quality ◽  
Experienced Fatigue ◽  
Health Related

Introduction: To estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of disability, from the societal perspective, in HUF 2015. Results: A total of 521 patients (mean age 47 years) participated; 85% were below retirement age, and of these, 47% were employed. Employment was related to disability and MS affected productivity at work for 82% of those working. Overall, 94% and 66% of patients experienced fatigue and cognitive difficulties as a problem, respectively. The mean utility and annual costs were 0.691 and 3,432,000HUF at Expanded Disability Status Scale (EDSS) 0–3, 0.491 and 5,262,000HUF at EDSS 4–6.5 and 0.076 and 6,235,000HUF at EDSS 7–9, respectively. The average cost of a relapse was estimated at 240,500HUF. Conclusion: This study illustrates the burden of MS on Hungarian patients and provides current data that are important for the development of health policies.

scholarly journals New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland

2017 ◽  
Vol 23 (2_suppl) ◽  
pp. 192-203 ◽  
Author(s):  
Pasquale Calabrese ◽  
Gisela Kobelt ◽  
Jenny Berg ◽  
Daniela Capsa ◽  
Jennifer Eriksson ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Work Capacity ◽  
Outcome Data ◽  
Current Data ◽  
Cross Sectional ◽  
Related Quality ◽  
Experienced Fatigue ◽  
Health Related ◽  
The Mean ◽  
Mean Cost

Introduction: To estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in CHF 2015. Results: A total of 721 patients (mean age 48 years) participated in Switzerland; 90% were below retirement age, and of these, 65% were employed. Employment was related to disease severity, and MS affected productivity at work for 69% of patients. Overall, 93% and 64% of patients experienced fatigue and cognition as a problem, respectively. The mean utility and annual costs were 0.799 and 29,600CHF at Expanded Disability Status Scale (EDSS) 0–3, 0.614 and 66,800CHF at EDSS 4–6.5 and 0.348 and 110,800CHF at EDSS 7–9, respectively. The mean cost of a relapse was estimated at 7600CHF. Conclusion: This study provides current data on MS in Switzerland that are important for development of health policies and to estimate the value of current and future treatments.

scholarly journals New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands

2017 ◽  
Vol 23 (2_suppl) ◽  
pp. 117-129 ◽  
Author(s):  
Bernard Uitdehaag ◽  
Gisela Kobelt ◽  
Jenny Berg ◽  
Daniela Capsa ◽  
Johan Dalén ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
The Netherlands ◽  
Work Capacity ◽  
Outcome Data ◽  
Current Data ◽  
Cross Sectional ◽  
Related Quality ◽  
Experienced Fatigue ◽  
Health Related ◽  
Mean Cost

Introduction: To estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and Methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015. Results: A total of 382 patients (mean age: 54 years) participated in the Netherlands; 81% were below retirement age and of these, 31% were employed. Employment was inversely related to disease severity, and MS affected productivity at work for 82% of patients. Overall, 96% and 73% of patients experienced fatigue and cognitive difficulties, respectively, as a problem. Mean utility and annual costs were 0.744 and €23,100 at Expanded Disability Status Scale (EDSS) 0–3, 0.595 and €32,300 at EDSS 4–6.5, and 0.297 and €50,500 at EDSS 7–9. The mean cost of a relapse was estimated at €3000. Conclusion: This study provides current data on MS in the Netherlands that are important for the development of health policies and to estimate the value of current and future treatments.

scholarly journals New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom

2017 ◽  
Vol 23 (2_suppl) ◽  
pp. 204-216 ◽  
Author(s):  
Alan Thompson ◽  
Gisela Kobelt ◽  
Jenny Berg ◽  
Daniela Capsa ◽  
Jennifer Eriksson ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Work Capacity ◽  
Outcome Data ◽  
Current Data ◽  
Cross Sectional ◽  
The United Kingdom ◽  
Related Quality ◽  
Experienced Fatigue ◽  
Health Related ◽  
Mean Cost

Introduction: In order to estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of disability, from the societal perspective, in EUR (2015). Results: A total of 779 patients (mean age = 57 years) participated; 72% were below retirement age and of these, 36% were employed. Employment was related to disease severity, and MS affected productivity at work for 84% of patients. Overall, 96% and 72% of the patients experienced fatigue and cognition as a problem. Mean utility and annual costs were 0.735 and 11,400GBP at Expanded Disability Status Scale (EDSS) = 0–3, 0.534 and 22,700GBP at EDSS = 4–6.5, and 0.135 and 36,500GBP at EDSS = 7–9. The mean cost of a relapse was estimated at 790GBP. Conclusion: This study illustrates the burden of MS on UK patients and provides current data on MS that are important for development of health policies.

scholarly journals New insights into the burden and costs of multiple sclerosis in Europe: Results for France

2017 ◽  
Vol 23 (2_suppl) ◽  
pp. 65-77 ◽  
Author(s):  
Christine Lebrun-Frenay ◽  
Gisela Kobelt ◽  
Jenny Berg ◽  
Daniela Capsa ◽  
Mia Gannedahl ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Work Capacity ◽  
Outcome Data ◽  
Current Data ◽  
Cross Sectional ◽  
Disability Status ◽  
Related Quality ◽  
Experienced Fatigue ◽  
Health Related

Introduction: To estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, in the societal perspective, in EUR 2015. Results: A total of 491 patients (mean age 47 years) participated; 82% were below retirement age, and of these 56% were employed. Employment was related to disease severity, and MS affected productivity at work for 90% of patients. Overall, 95% and 67% of patients experienced fatigue and cognition as a problem, respectively. The mean utility and annual costs were 0.735 and €22,600 at Expanded Disability Status Scale (EDSS) 0–3, 0.500 and €38,100 at EDSS 4–6.5, and 0.337 and €48,100 at EDSS 7–9, respectively. The average cost of a relapse was estimated at €2300. Conclusion: This study provides current data on MS in France that are important for developments of health policies and to estimate the value of current and future treatments.

scholarly journals New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic

2017 ◽  
Vol 23 (2_suppl) ◽  
pp. 41-52 ◽  
Author(s):  
Eva Havrdova ◽  
Gisela Kobelt ◽  
Jenny Berg ◽  
Daniela Capsa ◽  
Mia Gannedahl ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Czech Republic ◽  
Work Capacity ◽  
Outcome Data ◽  
Current Data ◽  
Cross Sectional ◽  
The Czech Republic ◽  
Related Quality ◽  
Experienced Fatigue ◽  
Health Related

Introduction: In order to estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, in the societal perspective, in CZK 2015. Results: A total of 747 patients (mean age 47 years) participated; 86% were below retirement age and of these, 49% were employed. Employment was related to disease severity, and MS affected productivity at work for 82% of those working. Overall, 92% and 66% of patients experienced fatigue and cognitive difficulties as a problem. Mean utility and annual costs were 0.832 and 257,000CZK at Expanded Disability Status Scale (EDSS) 0–3, 0.530 and 425,500CZK at EDSS 4–6.5 and 0.141 and 489,000CZK at EDSS 7–9. The average cost of a relapse was estimated at 12,600CZK. Conclusion: This study provides current data on MS in the Czech Republic that are important for the development of health policies.

Sign in / Sign up

Export Citation Format

Share Document